RA
CLDX icon

Royce & Associates’s Celldex Therapeutics CLDX Stock Holding History

Royce & Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-18,200
Closed -$9.67M – 1441
2013
Q3 		$9.67M Sell
18,200
-8,467
-32% -$2.9M 0.03% 674
2013
Q2 		$6.24M Buy
+26,667
New +$5.25M 0.02% 778

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Royce & Associates's CLDX Position: Q4 2013 in Review

Royce & Associates sold out of Celldex Therapeutics (CLDX) in Q4 2013, closing a stake of 18,200 shares — an estimated $9.67M sold.

Royce & Associates first reported a position in CLDX in Q2 2013 and held it in 2 quarters. The position peaked at $9.67M in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

  • Royce & Associates reported no remaining Celldex Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Royce & Associates sold 18,200 Celldex Therapeutics shares in Q4 2013, an estimated $9.67M.
  • Royce & Associates first reported a position in Celldex Therapeutics in Q2 2013 and held it in 2 quarters.
  • Royce & Associates's Celldex Therapeutics position peaked at $9.67M in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on Royce & Associates's 13F filing for Q4 2013, filed 10 Feb 2014.